Julie Jordan

Julie Jordan discloses dealings in 2 companies, chiefly Q32 Bio Inc. and Neurogene Inc. We count 11 filings; the first trade dates from 2 August 2023 and the latest from 26 March 2026.

Every open-market trade on record is a sale: 5 sales worth €18k. Besides market trades, the filings include 2 share grants and 4 option exercises. So far in 2026, the count stands at no purchases and 1 sale.

The record was last updated on 30 March 2026 with an open-market sale (€16k) in Neurogene Inc. The median gap between a trade and its publication by SEC (Form 4) is 4 days. Section 16 rules allow two business days to file each Form 4. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.